Rufinamide is a triazole derivative. The exact mechanism of action is unknown. However, it is thought that rufinamide modulates the activity of sodium channels and, in particular, prolongation of the inactive state of the channel.
Rufinamide is specifically indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.
Rufinamide is supplied as a 200mg or 400mg tablet for oral administration.
source:centerwatch
No comments:
Post a Comment